Analysts said the IBS pharmaceutical market would reach 1.2 billion US dollars in the seven major markets by 2009. The major markets are the USA, France, Germany, Italy, Spain, the UK, and Japan.
In 1999 the entire market, with sales totalling 426 million dollars, comprised of laxatives, anti-diarrheals, antispasmodics, and antidepressants, according to analysts Decision Resources, of Waltham, Massachusetts, USA.
|5-HT modulators will make up 60% of the IBS drug market by 2009.|
Their share of the market would shrink to 39% by 2009. 5-HT modulators would comprise nearly 60% of the market.
"The potential for these agents to treat multiple symptoms, e.g. altered motility and pain, and to increase the percentage of diagnosed and drug-treated patients, will expand the IBS market significantly," according to a Decision Resources study.
"We estimate that seven-market IBS sales for this class will reach 683 million dollars in 2009 and account for 59% of the IBS market."
The study predicted that antispasmodics' share of the market would fall from 42% to 17% because of the emergence of 5-HT modulators.
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com